Mark your calendar. July 23 24. FDA advisory committee reviewing BPC 157, TB 500, MOTS C, semax, epitalon, KPV, and DSIP for the 503A compounding list. The peptide landscape could shift significantly. Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # BPC 157 Banned: Key Facts on the Latest FDA Decision Affordable BPC 157 + TB 500 Injections Wolverine Peptide Therapy in South Florida Prescription, Cost, Dosage, Benefits, Side Effects FDA Removes BPC 157, TB 500 and 10 More Peptides from Category 2 (April 2026)